FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
This study is testing a special medical device called TheraSphere GBM, which delivers targeted radiation directly to a fast-growing type of brain tumor called glioblastoma. The main goal is to see how safe and feasible this new treatment is for patients whose tumor has returned after previous treatments.
You may be able to join if you are 18 or older, have a confirmed glioblastoma that has come back, and meet specific health and tumor size requirements. Certain past radiation treatments or tumor locations near critical brain areas may mean you cannot participate.
As a participant, you will receive the TheraSphere GBM device treatment and attend scheduled follow-up visits so the medical team can monitor your health and safety closely. You will also need to follow all study rules and undergo brain scans and tests.
The study is currently recruiting patients at medical centers in Birmingham, Alabama, and San Diego and San Francisco, California.
- 1Evaluating a new targeted radiation device for recurrent brain tumors.
- 2Currently looking for participants at multiple locations in the United States.
- 3Involves regular safety checks, health monitoring, and following study visits.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.